Hot Pursuit     05-Mar-21
Shilpa Medicare gets USFDA nod for arthritis drug
Shilpa Medicare has received United States Food and Drug Administration (USFDA)'s tentative approval for its abbreviated new drug application (ANDA), apremilast tablets, 10 mg, 20 mg, and 30 mg.

The ANDA was filed as 'First to File' submission on NCE -1 date to seek eligibility for 180 days exclusivity.

Apremilast tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene, used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2020 data, the US market for apremilast tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

The company's consolidated net profit dropped 86.07% to Rs 7.67 crore on a 19.25% fall in net sales to Rs 191.25 crore in Q3 FY21 over Q3 FY20.

The scrip fell 1% to currently trade at Rs 380.20 on the BSE.

Previous News
  Indices trade with stellar gains; pharma stocks in demand
 ( Market Commentary - Mid-Session 05-Jun-24   12:33 )
  Shilpa Medicare Hyderabad unit clears USFDA inspection with zero observations
 ( Hot Pursuit - 25-Jun-24   14:18 )
  Shilpa Medicare spurts as arm files DMF with USFDA
 ( Hot Pursuit - 05-Jun-24   11:15 )
  Shilpa Medicare rises after marketing partner launches pemetrexed formulation in US
 ( Hot Pursuit - 18-Apr-24   09:44 )
  Volumes jump at Shilpa Medicare Ltd counter
 ( Hot Pursuit - 21-Feb-23   14:30 )
  Shilpa Medicare announces launch of PEMRYDI RTU®
 ( Corporate News - 18-Apr-24   09:54 )
  Board of Shilpa Medicare recommends final dividend
 ( Corporate News - 24-May-22   14:12 )
  Shilpa Medicare board to mull rights issue
 ( Hot Pursuit - 21-Jun-23   08:43 )
  Shilpa Medicare Unit III R&D facility in Bengaluru clears USFDA review
 ( Hot Pursuit - 19-Nov-21   13:42 )
  Shilpa Medicare consolidated net profit declines 10.63% in the September 2020 quarter
 ( Results - Announcements 02-Nov-20   15:17 )
  Volumes soar at Shilpa Medicare Ltd counter
 ( Hot Pursuit - 24-May-22   14:30 )
Other Stories
  RVNL gains on emerging as L-1 bidder for Rs 133-cr railway project
  03-Jul-24   15:38
  Cholamandalam Financial Holdings Ltd leads losers in 'A' group
  03-Jul-24   15:00
  Sakuma Exports Ltd leads losers in 'B' group
  03-Jul-24   14:45
  NTPC power generation climbs 9.5% YoY in Q1
  03-Jul-24   14:41
  Volumes soar at MMTC Ltd counter
  03-Jul-24   14:30
  Oil and Gas shares fall
  03-Jul-24   14:00
  Real Estate stocks edge lower
  03-Jul-24   14:00
  Energy stocks edge lower
  03-Jul-24   14:00
  Sundaram-Clayton gains after board OKs to raise funds upto Rs 400 cr
  03-Jul-24   13:38
  JSW Infra's subsidiary concession agreement V.O. Chidambaranar Port Authority
  03-Jul-24   13:34
Back Top